Doç. Dr. BAŞAK ÇELTİKÇİ

Yayın Ağı

Makaleler 17

1. Genetic heterogeneity and metabolic reprogramming in breast cancer

DOLAŞ Y., BURUŞ A., ÇELTİKÇİ B.

Acta Medica , cilt.55, sa.4, ss.1-20, 2024 (TRDizin)

2. The effect of genetics and biochemistry on the pathogenesis of cholangiocarcinoma

ÜÇDAL M. T., BURUŞ A., ÇELTİKÇİ B.

INTERNATIONAL JOURNAL OF HEPATOBILIARY AND PANCREATIC DISEASES , cilt.14, sa.2, ss.1-14, 2024 (ESCI)

3. Cross Talk Between Genetics and Biochemistry in The Pathogenesis of Hepatocellular Carcinoma

ÜÇDAL M. T., BURUŞ A., ÇELTİKÇİ B.

Hepatology forum , cilt.5, sa.3, ss.150-160, 2024 (ESCI, TRDizin)

4. A novel brick on the wall of non-alcoholic fatty liver disease (NAFLD): Nuclear receptor coactivator 4 (NCOA4)

Üçdal M. T., Burus A., Celtikci B., Yasemin Balaban H. Y.

MEDICAL HYPOTHESES , cilt.181, 2023 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

5. The effect of ACE2 receptor, IFN-γ, and TNF-α polymorphisms on the severity and prognosis of the disease in SARS-CoV-2 infection

Esen S. G., Basak C., Leyla Ö., Aslıhan A., Evrim Eylem A.

Journal of Investigative Medicine , cilt.71, sa.5, ss.526-535, 2023 (SCI-Expanded, Scopus)

6. Evaluating the Correlation of Mortality and Biochemical Parameters in Community-acquired and Hospital-acquired Pneumonia

ÇELTİKÇİ B., GÜLENSOY E. S.

Acta Medica , cilt.54, sa.1, ss.71-79, 2023 (TRDizin)

7. A Crosstalk Between Dual-Specific Phosphatases and Dual-Specific Protein Kinases Can Be A Potential Therapeutic Target for Anti-cancer Therapy.

Celtikci B.

Advances in experimental medicine and biology , cilt.1275, ss.357-382, 2021 (SCI-Expanded, Scopus)

8. Regulation And Effect Of Telomerase And Telomeric Length In Stem Cells.

Celtikci B., Erkmen G. K., Dikmen Z. G.

Current stem cell research & therapy , cilt.16, ss.809-823, 2021 (SCI-Expanded, Scopus)

9. HDAC Inhibition Overcomes Acute Resistance to MEK Inhibition in BRAF-Mutant Colorectal Cancer by Downregulation of c-FLIPL

Carson R., ÇELTİKÇİ B., Fenning C., Javadi A., Crawford N., Perez-Carbonell L., et al.

CLINICAL CANCER RESEARCH , cilt.21, sa.14, ss.3230-3240, 2015 (SCI-Expanded, Scopus)

10. Four novel mutations in the beta-galactosidase gene identified in infantile type of GM1 gangliosidosis

CELTIKCI B., AYDIN H. I., Sivri S., Sonmez M., TOPÇU M., ÖZKARA H. A.

CLINICAL BIOCHEMISTRY , cilt.45, ss.571-574, 2012 (SCI-Expanded, Scopus)

11. Two novel alpha-galactosidase A mutations causing Fabry disease: A missense mutation M11V in a heterozygote woman and a nonsense mutation R190X in a hemizygote man.

CELTIKCI B., TOPÇU M., ÖZKARA H. A.

Clinical biochemistry , cilt.44, ss.809-12, 2011 (SCI-Expanded, Scopus)

12. Establishment of Green Fluorescent Protein Expressing CHO Cells by Stable Transfection Using Activated Dendrimers and G418 Selection

CELTIKCI B., PURALI N., ÖZKARA H. A.

TURKISH JOURNAL OF BIOCHEMISTRY-TURK BIYOKIMYA DERGISI , cilt.35, sa.4, ss.340-343, 2010 (SCI-Expanded, Scopus, TRDizin)

13. Methotrexate-induced apoptosis is enhanced by altered expression of methylenetetrahydrofolate reductase

ÇELTİKÇİ B., Lawrance A. K., Wu Q., Rozen R.

ANTI-CANCER DRUGS , cilt.20, sa.9, ss.787-793, 2009 (SCI-Expanded, Scopus)

14. Protective role of 27bp repeat polymorphism in intron 4 of eNOS gene in lacunar infarction

Yemisci M., Sinici I., ÖZKARA H. A., Hayran M., AY H., CELTIKCI B., et al.

FREE RADICAL RESEARCH , cilt.43, sa.3, ss.272-279, 2009 (SCI-Expanded, Scopus)

15. Protective role of 27bp repeat polymorphism in intron 4 of eNOS gene in lacunar infarction (vol 43, pg 272, 2009)

Yemisci M., Lay İ., Oezkara H. A., Hayran M., Ay H., Celtikci B., et al.

FREE RADICAL RESEARCH , cilt.43, sa.3, ss.273-279, 2009 (SCI-Expanded, Scopus)

16. Altered expression of methylenetetrahydrofolate reductase modifies response to methotrexate in mice

ÇELTİKÇİ B., Leclerc D., Lawrance A. K., Deng L., Friedman H. C., Krupenko N. I., et al.

PHARMACOGENETICS AND GENOMICS , cilt.18, sa.7, ss.577-589, 2008 (SCI-Expanded, Scopus)

17. Increased hexosaminidase activity in antipsychotic-induced extrapyramidal side effects: Possible association with higher occurrence in bipolar disorder patients

Tunca Z., RESMI H., ÖZKARA H. A., Ciliv G., CELTIKCI B., ALPTEKIN K., et al.

PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY , cilt.32, sa.5, ss.1214-1220, 2008 (SCI-Expanded, Scopus)

Hakemli Bilimsel Toplantılarda Yayımlanmış Bildiriler 11

1. Radgohar, A; Burus, A; Ucdal, M; Yalcinkaya, A; Balaban, Y; Celtikci, B. Evaluation of the molecular basis of autoimmune cholestatic liver diseases via serum cytokine release. FEBS OPEN BIO. 2025; 15 (Supp2), 450-451Meeting Abstract LB-R-41-07

BALABAN H. Y., BURUŞ A., ÜÇDAL M., ÇELTİKÇİ B.

FEBS OPEN BIO, Amerika Birleşik Devletleri, 01 Aralık 2025, (Tam Metin Bildiri)

2. ROLE OF NUCLEAR RECEPTOR COACTIVATOR 4 (NCOA4) GENE VARIANTS IN METABOLIC HYPERFERRITINEMIA OBSERVED IN METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH)

BALABAN H. Y., ÜÇDAL M., ŞİMŞEK C., BURUŞ A., ÇELTİKÇİ B.

eug2025, Almanya, 4 - 07 Ekim 2025, (Tam Metin Bildiri)

3. The Cytokine Profile of Primary Biliary Cholangitis (PBC): Is PBC an Autoinflammatory vs. Autoimmune Disease?

RADGOHAR A., ÜÇDAL M. T., BURUŞ A., YALÇINKAYA A., BALABAN H. Y., ÇELTİKÇİ B.

41. Ulusal Gastroenteroloji Haftası, Antalya, Türkiye, 27 Kasım 2024, (Özet Bildiri)

4. Two forms of a disease in the same family: compound heterozygosity in the father and his sister both with corneal cystinosis, and heterozygous daughter and his other sister both having risks for nephropathic cystinosis

ÇELTİKÇİ B., Kazancı B.

European Human Genetics Virtual Conference, Berlin, Almanya, 06 Haziran 2020, (Tam Metin Bildiri)

5. Two families having Huntington’xxs disease with two different clinical presentations

ÇELTİKÇİ B., Kaplan F., SAYIN R.

EUROPEAN HUMAN GENETICS CONFERENCE, Gothenburg, İsveç, 15 - 18 Haziran 2019, cilt.27, ss.1865, (Tam Metin Bildiri)

6. The effects of human chorionic gonadotropin-based hormonal therapy on the expression levels of proliferating cell nuclear antigen

ÇELTİKÇİ B., TANGAL S., ÖZER L.

13. Balkan Congress of Human Genetics, 17 - 20 Nisan 2019, (Tam Metin Bildiri)

7. The role of JAK1/2-STAT3 as acute resistance mechanism to MEK inhibition in BRAF-mutant colorectal cancer cell lines.

ÇELTİKÇİ B., Carson R., Johnston P. G., Van Schaeybroeck S.

JOURNAL OF CLINICAL ONCOLOGY, Chicago, 30 Mayıs - 03 Haziran 2014, cilt.32 Sürdürülebilir Kalkınma

8. The role of JAK1/2-STAT3 as acute resistance mechanism to MEK inhibition in BRAF mutant colorectal cancer

Carson R., ÇELTİKÇİ B., Johnston P. G., Van Schaeybroeck S., Dunne P.

MOLECULAR CANCER THERAPEUTICS, 10 - 13 Kasım 2013, cilt.12 Sürdürülebilir Kalkınma

9. The establishment of Green Fluorescent Protein expressing CHO cells by stable transfection using activated dendrimers and G418 selection

ÇELTİKÇİ B., ÖZKARA H. A., PURALI N.

FEBS JOURNAL, Prague, 4 - 09 Temmuz 2009, cilt.276, ss.215-216

10. Increased hexosaminidase activity in psychiatric patients with drug induced extrapramidal side effects

Tunca Z., Resmi H., Ozkara A., Ciliv G., Celtikci B., Alptekin K., et al.

62nd Annual Scientific Meeting of the Society-of-Biological-Psychiatry, California, Amerika Birleşik Devletleri, 01 Ocak 2007, cilt.61, (Özet Bildiri)

11. Protective role of 27 bp deletion polymorphism in intron 4 of eNOS gene in cerebral small-vessel disease

Yemisci M., Sinici I., ÖZKARA H. A., HAYRAN K. M., ay h., ÇELTİKÇİ B., et al.

FEBS JOURNAL, İstanbul, Türkiye, 24 - 29 Haziran 2006

Metrikler

Yayın

Yayın (WoS)

Yayın (Scopus)

Atıf (WoS)

162

H-İndeks (WoS)

Atıf (Scopus)

136

H-İndeks (Scopus)

Atıf (Scholar)

257

H-İndeks (Scholar)

Proje

Açık Erişim

BM Sürdürülebilir Kalkınma Amaçları

Yayınlar & Eserler